Article

Transcatheter aortic valve implantation for high-risk patients with severe aortic stenosis: A systematic review

Department of Cardiothoracic Surgery, The University of Sydney, Royal Prince Alfred Hospital, Sydney 2050, Australia.
The Journal of thoracic and cardiovascular surgery (Impact Factor: 3.41). 10/2009; 139(6):1519-28. DOI: 10.1016/j.jtcvs.2009.08.037
Source: PubMed

ABSTRACT The present systematic review objectively assessed the safety and clinical effectiveness of transcatheter aortic valve implantation for patients at high surgical risk with severe aortic stenosis.
Electronic searches were performed in 6 databases from January 2000 to March 2009. The end points included feasibility, safety, efficacy, and durability. Clinical effectiveness was synthesized through a narrative review with full tabulation of results of all included studies.
The current evidence on transcatheter aortic valve implantation for aortic stenosis is limited to short-term observational studies. The overall procedural success rates ranged from 74% to 100%. The incidence of major adverse events included 30-day mortality (0%-25%), major ventricular tachyarrhythmia (0%-4%), myocardial infarction (0%-15%), cardiac tamponade (2%-10%), stroke (0%-10%), conversion to surgery (0%-8%), moderate to major paravalvular leak (4%-35%), vascular complication (8%-17%), valve-in-valve procedure (2%-12%), and aortic dissection/perforation (0%-4%). The overall 30-day major adverse cardiovascular and cerebral events ranged from 3% to 35%. The mean aortic valve area ranged from 0.5 to 0.8 cm(2) before and 1.3 to 2.0 cm(2) after transcatheter aortic valve implantation. The mean pressure gradient ranged from 34 to 58 mm Hg before and 3 to 12 mm Hg after transcatheter aortic valve implantation. There was no significant deterioration in echocardiography measurements during the assessment period. Death rate at 6 months postprocedure ranged from 18% to 48%. No studies had adequate follow-up to reliably evaluate long-term outcomes.
The procedure has a potential for serious complications. Although short-term efficacy based on echocardiography measurements is good, there is little evidence on long-term outcomes. The use of transcatheter aortic valve implantation should be considered only within the boundaries of clinical trials.

0 Bookmarks
 · 
196 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: R ealizado pela primeira vez em 2002, o implante percutâneo de bioprótese aórtica tem despertado significativo interesse nos últimos anos, por tra-tar-se de alternativa segura e menos invasiva para pacientes portadores de estenose aórtica e alto risco cirúrgico. Atualmente, dois tipos de prótese são dispo-níveis e comercializadas na Europa e diversas outras estão sendo investigadas, e mais de 20 mil pacientes foram tratados até 2010. Vários registros têm sido pu-blicados e importantes estudos randomizados e compa-rativos com a cirurgia de troca valvar e com o tratamento conservador estão disponíveis (SOURCE, PARTNER) ou em andamento (UK TAVI Trial, SURTAVI). Em nosso País, cerca de 200 pacientes já foram submetidos ao implante da bioprótese autoexpansível CoreValve TM (Medtronic Inc., Minneapolis, Estados Unidos), e vislum-bra-se, ainda no primeiro semestre, o início da utili-zação da bioprótese balão-expansível Edwards-SAPIEN TM (Edwards Lifesciences, Irvine, Estados Unidos). Nesta edição da Revista Brasileira de Cardiologia Invasiva, somos apresentados a duas das experiências nacionais de implante valvular aórtico percutâneo. Lemos et al. 1 descrevem os resultados clínicos dos primeiros 75 pacientes tratados com a prótese CoreValve TM em dois centros, no Brasil (n = 14) e na Itália (n = 61); e Bernardi et al. 2 , por sua vez, relatam a evolução de dois anos dos primeiros 4 pacientes submetidos ao procedimento no Sul do País. Os resul-tados das duas publicações exprimem tanto os notá-veis progressos alcançados como os grandes desafios a serem transpostos para a ampliação nas indicações desse procedimento.
    03/2011; 19(1). DOI:10.1590/S2179-83972011000100003
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Many patients deemed inoperable for surgical aortic valve replacement (SAVR) have been treated successfully by transcatheter aortic-valve replacement (TAVR). This meta-analysis is designed to evaluate the performance of TAVR in comparison with SAVR.
    08/2014; 1(1):e000013. DOI:10.1136/openhrt-2013-000013
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Acute kidney injury (AKI) represents a major complication following aortic valve replacement in elderly patients. The aim of this study was to determine possible risk factors for AKI and to find the ideal strategy, minimally invasive valve replacement (MIS-AVR) or transapical valve implantation (TA-TAVI), regarding the postoperative renal outcome. Methods A total of 133 patients (age ≥ 75 years, 67 male) with severe aortic stenosis were included over 2 years: 42% were treated with MIS-AVR, 58% underwent TA-TAVI procedure. AKI was considered as a postprocedural 1.5× increase in creatinine or an increase of > 0.3 mg/dL/48 hours. Group differences were tested with chi-square or t-test. AKI risk assumption was analyzed in multiple multivariate logistic regression models. Results EuroSCORE II-related risk assumption was 8.7 ± 6.9 for TA-TAVI and 4.5 ± 5.7 for MIS-AVR (p < 0.001). The overall 30-day survival rate was 93%. Fifty-eight patients developed a risk for AKI and 13 developed a manifest renal injury/failure. Logistic regression analysis revealed a higher AKI risk for TA-TAVI (odds ratio, OR = 2.58; 95% confidence interval, CI = 1.18, 5.63; p = 0.017). EuroSCORE II (OR = 0.98; 95% CI = 0.92, 1.04; p = 0.433); preoperative creatinine (OR = 1.78; 95% CI = 0.67, 4.77; p = 0.249) and estimated glomerular filtration rate (OR = 1.00; 95% CI = 0.97, 1.02; p = 0.655) had no impact on AKI. A regression model adjusting for the variables age, gender, body mass index (BMI), diabetes, and procedure type revealed a higher AKI rate for male gender (OR = 2.41; 95% CI = 1.13, 5.11; p = 0.022). Operation time and radio-contrast media volume had no influence on the AKI-occurrence. There was no correlation between AKI and early mortality. Conclusion A higher risk for AKI after TA-TAVI should be considered in the therapy decision, especially in elderly male patients because MIS-AVR still yields excellent results.
    The Thoracic and Cardiovascular Surgeon 07/2014; 62(6). DOI:10.1055/s-0034-1376201 · 1.08 Impact Factor

Full-text (2 Sources)

Download
60 Downloads
Available from
Jun 4, 2014